Predictive biomarkers in radioresistant rectal cancer: A systematic review

Anna Slipsager; Sofie N. Henrichsen; Ursula G. Falkmer; Karen Dybkær; Mattias Belting; Laurids Ø. Poulsen

doi:10.1016/j.critrevonc.2023.103991

Predictive biomarkers in radioresistant rectal cancer: A systematic review

Anna Slipsager^*, Sofie N. Henrichsen, Ursula G. Falkmer, Karen Dybkær, Mattias Belting, Laurids Ø. Poulsen

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

57 Downloads (Pure)

Abstract

Background and aims: The treatment of locally advanced rectal cancer often consists of neoadjuvant chemoradiotherapy followed by surgery. However, approximately 15% of patients show no response to this neoadjuvant chemoradiotherapy. This systematic review aimed to identify biomarkers of innate radioresistant rectal cancer.

Method: Through a systematic literature search, 125 papers were included and analyzed using ROBINS-I, a Cochrane risk of bias tool for non-randomized studies of interventions. Both statistically significant and nonsignificant biomarkers were identified. Biomarkers mentioned more than once in the results or biomarkers with a low or moderate risk of bias were included as the final results.

Results: Thirteen unique biomarkers, three genetic signatures, one specific pathway, and two combinations of two or four biomarkers were identified. In particular, the connection between HMGCS2, COASY, and PI3K-pathway seems promising. Future scientific research should focus on further validating these genetic resistance markers.

Original language	English
Article number	103991
Journal	Critical Reviews in Oncology/Hematology
Volume	186
Number of pages	6
ISSN	1040-8428
DOIs	https://doi.org/10.1016/j.critrevonc.2023.103991
Publication status	Published - Jun 2023

Bibliographical note

Keywords

Molecular biomarker
Neoadjuvant therapy
Radiotherapy
Rectal Neoplasms
Resistance

Access to Document

10.1016/j.critrevonc.2023.103991Licence: CC BY-NC-ND 4.0

Slipsager (2023) Predictive biomarkers in radioresistant rectal cancerFinal published version, 547 KBLicence: CC BY-NC-ND 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{3ae7992745e74e94a0af4f52c0037aa7,

title = "Predictive biomarkers in radioresistant rectal cancer: A systematic review",

abstract = "Background and aims: The treatment of locally advanced rectal cancer often consists of neoadjuvant chemoradiotherapy followed by surgery. However, approximately 15% of patients show no response to this neoadjuvant chemoradiotherapy. This systematic review aimed to identify biomarkers of innate radioresistant rectal cancer.Method: Through a systematic literature search, 125 papers were included and analyzed using ROBINS-I, a Cochrane risk of bias tool for non-randomized studies of interventions. Both statistically significant and nonsignificant biomarkers were identified. Biomarkers mentioned more than once in the results or biomarkers with a low or moderate risk of bias were included as the final results.Results: Thirteen unique biomarkers, three genetic signatures, one specific pathway, and two combinations of two or four biomarkers were identified. In particular, the connection between HMGCS2, COASY, and PI3K-pathway seems promising. Future scientific research should focus on further validating these genetic resistance markers.",

keywords = "Molecular biomarker, Neoadjuvant therapy, Radiotherapy, Rectal Neoplasms, Resistance",

author = "Anna Slipsager and Henrichsen, {Sofie N.} and Falkmer, {Ursula G.} and Karen Dybk{\ae}r and Mattias Belting and Poulsen, {Laurids {\O}.}",

year = "2023",

month = jun,

doi = "10.1016/j.critrevonc.2023.103991",

language = "English",

volume = "186",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier",

}

TY - JOUR

T1 - Predictive biomarkers in radioresistant rectal cancer

T2 - A systematic review

AU - Slipsager, Anna

AU - Henrichsen, Sofie N.

AU - Falkmer, Ursula G.

AU - Dybkær, Karen

AU - Belting, Mattias

AU - Poulsen, Laurids Ø.

PY - 2023/6

Y1 - 2023/6

N2 - Background and aims: The treatment of locally advanced rectal cancer often consists of neoadjuvant chemoradiotherapy followed by surgery. However, approximately 15% of patients show no response to this neoadjuvant chemoradiotherapy. This systematic review aimed to identify biomarkers of innate radioresistant rectal cancer.Method: Through a systematic literature search, 125 papers were included and analyzed using ROBINS-I, a Cochrane risk of bias tool for non-randomized studies of interventions. Both statistically significant and nonsignificant biomarkers were identified. Biomarkers mentioned more than once in the results or biomarkers with a low or moderate risk of bias were included as the final results.Results: Thirteen unique biomarkers, three genetic signatures, one specific pathway, and two combinations of two or four biomarkers were identified. In particular, the connection between HMGCS2, COASY, and PI3K-pathway seems promising. Future scientific research should focus on further validating these genetic resistance markers.

AB - Background and aims: The treatment of locally advanced rectal cancer often consists of neoadjuvant chemoradiotherapy followed by surgery. However, approximately 15% of patients show no response to this neoadjuvant chemoradiotherapy. This systematic review aimed to identify biomarkers of innate radioresistant rectal cancer.Method: Through a systematic literature search, 125 papers were included and analyzed using ROBINS-I, a Cochrane risk of bias tool for non-randomized studies of interventions. Both statistically significant and nonsignificant biomarkers were identified. Biomarkers mentioned more than once in the results or biomarkers with a low or moderate risk of bias were included as the final results.Results: Thirteen unique biomarkers, three genetic signatures, one specific pathway, and two combinations of two or four biomarkers were identified. In particular, the connection between HMGCS2, COASY, and PI3K-pathway seems promising. Future scientific research should focus on further validating these genetic resistance markers.

KW - Molecular biomarker

KW - Neoadjuvant therapy

KW - Radiotherapy

KW - Rectal Neoplasms

KW - Resistance

U2 - 10.1016/j.critrevonc.2023.103991

DO - 10.1016/j.critrevonc.2023.103991

M3 - Review article

C2 - 37059272

SN - 1040-8428

VL - 186

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 103991

ER -

Predictive biomarkers in radioresistant rectal cancer: A systematic review

Abstract

Bibliographical note

Keywords

Access to Document

AUB Link

Fingerprint

Cite this